Search Result

Results for "

sst5

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenylate Cyclase (2) Somatostatin Receptor (19) Urotensin Receptor (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (3) Endocrinology (9) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (8)

Inhibitors & Agonists

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1203

BIM-23056	Somatostatin Receptor	Neurological Disease
BIM 23056, a linear octapeptide, is a potent *sst3* and *sst5* somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-P1932

Cortistatin-14	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 is a neuropeptide that shares structural similarities with somatostatin, working by binding to somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) has anticonvulsant, neuroprotective effects, and significant anti-inflammatory properties .

HY-P1932A

Cortistatin-14 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 (TFA), a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties .

HY-P1202

CYN 154806 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806, a cyclic octapeptide, is a potent and selective *somatostatin sst2 receptor* antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

HY-P1202A

CYN 154806 TFA 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806 TFA, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

HY-P2090A

Angiopeptin TFA	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak *sst₂/sst₅* receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .

HY-P1203A

BIM-23056 TFA	Somatostatin Receptor	Neurological Disease
BIM 23056 TFA, a linear octapeptide, is a potent *sst3* and *sst5* somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-P4469

PRL 3195	Somatostatin Receptor Urotensin Receptor	Cardiovascular Disease
PRL 3195 is a somatostatin receptor antagonist with K_is of 6, 17, 66, 1000 and 1000 nM for human somatostatin receptors (sst₅, sst₂, sst₃, sst₁ and sst₄, respectively) .

HY-164040

Zavolosotine	Somatostatin Receptor	Metabolic Disease
Zavolosotine (Compound 1) is an orally active agonist for somatostatin receptor type 5 (SST5) with EC₅₀ <1 nM. Zavolosotine inhibits insulin and glucagon secretion, increases levels of glucagon in blood in rat model .

HY-P2090

Angiopeptin	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak *sst₂/sst₅* receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research .

HY-P1206

CH 275	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM . CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively . CH 275 can be used for the research of alzheimer’s disease .

HY-79135

Pasireotide ditrifluoroacetate 5 Publications Verification SOM230 ditrifluoroacetate; Pasireotide TFA salt	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide ditrifluoroacetate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-79136

Pasireotide L-aspartate salt 5 Publications Verification SOM230 L-aspartate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) L-aspartate salt, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide L-aspartate salt exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-108768

Pasireotide pamoate SOM230 pamoate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) pamoate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide pamoate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-16381

Pasireotide 5 Publications Verification SOM230	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-16381A

Pasireotide acetate 5 Publications Verification SOM230 acetate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-16381B

Pasireotide (diaspartate) SOM230 (diaspartate)	Somatostatin Receptor	Neurological Disease Cancer
Pasireotide (SOM230) diaspartate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide diaspartate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-111615

J-2156	Somatostatin Receptor	Neurological Disease
J-2156 is a high potent, selective *somatostatin receptor type 4 (SST4 receptor)* agonist with IC₅₀s of 0.05 nM and 0.07 nM for human and rat SST4 receptors, respectively. J-2156 is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

HY-111615A

J-2156 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
J-2156 TFA is a high potent, selective *somatostatin receptor type 4 (SST₄* receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST₄* receptors, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

Cat. No.	Product Name	Target	Research Area

HY-P1203

BIM-23056	Somatostatin Receptor	Neurological Disease
BIM 23056, a linear octapeptide, is a potent *sst3* and *sst5* somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-P1932

Cortistatin-14	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 is a neuropeptide that shares structural similarities with somatostatin, working by binding to somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) has anticonvulsant, neuroprotective effects, and significant anti-inflammatory properties .

HY-P1932A

Cortistatin-14 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 (TFA), a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties .

HY-P1202

CYN 154806 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806, a cyclic octapeptide, is a potent and selective *somatostatin sst2 receptor* antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

HY-P1202A

CYN 154806 TFA 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806 TFA, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

HY-P2090A

Angiopeptin TFA	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak *sst₂/sst₅* receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .

HY-P1206

CH 275	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM . CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively . CH 275 can be used for the research of alzheimer’s disease .

HY-P1203A

BIM-23056 TFA	Somatostatin Receptor	Neurological Disease
BIM 23056 TFA, a linear octapeptide, is a potent *sst3* and *sst5* somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-P4469

PRL 3195	Somatostatin Receptor Urotensin Receptor	Cardiovascular Disease
PRL 3195 is a somatostatin receptor antagonist with K_is of 6, 17, 66, 1000 and 1000 nM for human somatostatin receptors (sst₅, sst₂, sst₃, sst₁ and sst₄, respectively) .

HY-P2090

Angiopeptin	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak *sst₂/sst₅* receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research .

HY-108768

Pasireotide pamoate SOM230 pamoate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) pamoate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide pamoate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-16381

Pasireotide 5 Publications Verification SOM230	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-16381A

Pasireotide acetate 5 Publications Verification SOM230 acetate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-111615A

J-2156 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
J-2156 TFA is a high potent, selective *somatostatin receptor type 4 (SST₄* receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST₄* receptors, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.